About Luwei
Shenzhen Luwei Biotechnology (Biomanifold Technology) Co., Limited, of which the technology team has a total of more than 30 years industrial experience in highly successful IVD companies in the United States; of which the operation team comes from the founder of a local public company and strives to the second entrepreneurship adventure, is committed to the research and development of molecular diagnostic clinical applications suitable for the Chinese heritage and other heritages, covering cancer and other severe diseases. The technology anchor point is the pioneering algorithm models with genomic transcriptome, which provides clinically actionable multi-gene diagnosis products for doctors and patients, including cancer recurrence, disease-free survival, overall survival, treatment response, early diagnosis, and prognosis evaluation, to ensure doctors and patients make data-driven precise medication decisions as to postoperative chemotherapy, treatment optimization, drug effect evaluation, disease surveillance and so on. Biomanifold Technology is committed to providing IVD products and third-party clinical laboratory services for clinicians, patients and pharmaceutical companies, so as to make due contributions to promoting the advanced precision medicine in China and across the globe.
READ MOREOur Products
Human Serum/Plasma Poly-IgA Immune Complex Assay Kit (ELISA)
NephroPlex™ kit, developed by Shenzhen Luwei Biotechnology Limited, is based on exclusively patented molecular probe technology to detect circulated poly-IgA immune complex in the peripheral blood. The renal deposition of Poly-IgA immune complex is mainly responsible for the pathological onset of IgA nephropathy. Experiments have verified that this indicator can be an excellent indicator for the assessment of immune activity of patients with IgA nephropathy.
As a first-in-class specific molecular biomarker of IgA nephropathy in the peripheral blood, Human Serum/Plasma Poly-IgA Immune Complex Assay Kit (ELISA) will lead a major breakthrough in the immune activity monitoring, companion diagnosis, fast turnaround treatment assessment, and life cycle management of patients with diagnosed IgA nephropathy; and early stage of IgA nephropathy diagnosis and risk assessment for patience with abnormal renal activities such as proteinuria and hematuria.
Breast Cancer Recurrence Risk Assessment
The core members of the successful American product "Breast Cancer 21-Gene Recurrence Score" lead the way in modeling the Asian population to accurately assess the risk of breast cancer recurrence and recommend the most appropriate treatment plan.
Lung Cancer Recurrence Risk Assessment
We uses 20+ years of industrial R&D big data to create AI algorithm models to accurately classify different lung cancer risk groups, assess recurrence risk, and guide personalized treatment plans.